Thinking in Frames

Novo Nordisk's Weight-Loss Revolution

7 min · 22 jan 2025
aflevering Novo Nordisk's Weight-Loss Revolution cover

Beschrijving

Novo Nordisk's success with its GLP-1 receptor agonists, Ozempic and Wegovy, is examined, highlighting the intense competition in the weight-loss drug market. The text explores various factors influencing the company's dominance, including market demand driven by the obesity epidemic, regulatory hurdles and pricing strategies, and internal factors such as strong R&D and strategic alignment. Technological advancements and social trends also played crucial roles. Despite side effects and high costs, the drugs' effectiveness has fueled significant demand.

Reacties

0

Wees de eerste die een reactie plaatst

Meld je nu aan en word lid van de Thinking in Frames community!

Begin hier

2 maanden voor € 1

Daarna € 9,99 / maand · Elk moment opzegbaar.

  • Podcasts die je alleen op Podimo hoort
  • 20 uur luisterboeken / maand
  • Gratis podcasts

Alle afleveringen

8 afleveringen